Suchergebnisse - "Cho, Daniel"

PubPharm (8)

1

Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma : a pathological, clinical and outcome study

enthalten in: Histopathology | 2021

von Kmeid, M. | Lukose, G. | Hodge, K. | +3

2

PD-1 blockade in recurrent or metastatic cervical cancer : Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

enthalten in: Gynecologic oncology | 2020

von Rischin, D. | Gil-Martin, M. | González-Martin, A. | +19

3

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Martini, J. | Plimack, E. | Choueiri, T. | +10

4

Treatment selection for patients with metastatic renal cell carcinoma

enthalten in: Cancer | 2009

von Atkins, M. | Choueiri, T. | Cho, D. | +2

5

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

enthalten in: Clinical genitourinary cancer | 2007

von Cho, D. | Signoretti, S. | Dabora, S. | +9

6

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2007

von Cho, D. | Signoretti, S. | Regan, M. | +2

7

Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools

enthalten in: Current urology reports | 2006

von Cho, D. | McDermott, D. | Atkins, M.

8

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)

enthalten in: Urologic oncology | 2003

von Cho, D. | Di Blasio, C. | Rhee, A. | +1

1
[1]